Home | Welcome to Contract Pharma   
Last Updated Friday, March 27 2015


Pfizer Makes Final Bid for AstraZeneca

Published May 19, 2014
Pfizer has made its fourth and final proposal to acquire AstraZeneca in a transaction valued at $120 billion, with 45% in cash. This latest offer represents a 45% increase of the total price and values AstraZeneca shares at £55 ($92.48) each. AstraZeneca declined to comment, but is reviewing the statement Pfizer issued.
Pfizer set forth terms of an improved proposal with a value of £53.50, with Pfizer and AstraZeneca shareholders owning approximately 74% and 26%, respectively, of the combined company. The initial proposal dating back to January valued the company at $98.7 billion.
Pfizer confirmed that it will not make a hostile offer directly to AstraZeneca shareholders and will only proceed with an offer with the recommendation of the board of directors of AstraZeneca
Both companies have aging portfolios and losses due to generic competition. Sales for each company fell 6% in 2013 with Pfizer's sales at $51.6 billion and AstraZeneca's at $25.7 billion.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On